Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15738038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Herceptin (trastuzumab), a new a chemotherapeutic agent, is a monoclonal antibody that blocks the human epidermal growth factor receptor 2 protein. There is no reported experience with use of this agent during pregnancy and possible effects on the fetus. A patient with breast cancer was treated with Herceptin during pregnancy. This treatment was associated with anhydramnios, which resolved slowly after the drug was discontinued. Although listed as a category B drug, experience with Herceptin in human pregnancy is limited, and it should be used with caution. Investigation of the role of human epidermal growth factor receptor 2 protein in the embryonic kidney may further our understanding of amniotic fluid dynamics.
Medical subject headings
- Antibodies, Monoclonal
- Breast Neoplasms
- Carcinoma, Ductal, Breast
- Oligohydramnios
- Pregnancy Complications, Neoplastic